Opinion/decision on a Paediatric investigation plan (PIP): Velsipity, etrasimod, decision type: PM: decision on the application for modification of an agreed PIP, therapeutic area: Gastrointestinal disorders, PIP number: EMA/PE/0000184081

Opinion/decision on a Paediatric investigation plan (PIP): Ebvallo, tabelecleucel, decision type: PM: decision on the application for modification of an agreed PIP, therapeutic area: Blood and lymphatic system disorders, PIP number: EMA/PE/0000183827

Opinion/decision on a Paediatric investigation plan (PIP): Livtencity, Maribavir, decision type: PM: decision on the application for modification of an agreed PIP, therapeutic area: Infections and infestations, PIP number: EMA/PE/0000182607

EMA/PE/0000182245

Opinion/decision on a Paediatric investigation plan (PIP): Venclyxto, venetoclax, decision type: PM: decision on the application for modification of an agreed PIP, therapeutic area: Blood and lymphatic system disorders, PIP number: EMA/PE/0000182075

EMA/PE/0000181243

Opinion/decision on a Paediatric investigation plan (PIP): Zegalogue, Dasiglucagon, decision type: PM: decision on the application for modification of an agreed PIP, therapeutic area: Endocrine disorders, PIP number: EMA/PE/0000181174

EMA/PE/0000181050

Minutes of the HMPC meeting 19-21 January 2026

Opinion of the CVMP on the establishment of maximum residue limits: Fluralaner ( EMEA/V/MRL/004380/EXTN/0002)